It would be also interesting to assess whether NSPs concentration in plasma or NSPs to AAT ratios could reflect the advanced stages of NAFLD and could be used as non-invasive markers for advanced stages of the disease. The gene discussed is SERPINA1; the disease is metabolic dysfunction-associated steatotic liver disease.